190 related articles for article (PubMed ID: 21790286)
1. Oralair®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis.
Hong J; Bielory L
Expert Rev Clin Immunol; 2011 Jul; 7(4):437-44. PubMed ID: 21790286
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
4. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
5. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
6. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
7. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
8. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
9. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
Serrano E; Wahn HU; Didier A; Bachert C
Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
[TBL] [Abstract][Full Text] [Related]
10. Sustained clinical efficacy of sublingual immunotherapy with a high-dose grass pollen extract.
Kuna P; Samolinski B; Worm M; Pfaar O; Klimek L;
Eur Ann Allergy Clin Immunol; 2011 Aug; 43(4):117-21. PubMed ID: 21980799
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
12. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
Larenas-Linnemann D
Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
[TBL] [Abstract][Full Text] [Related]
13. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
Kleine-Tebbe J; Ribel M; Herold DA
Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193
[TBL] [Abstract][Full Text] [Related]
14. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
15. [Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
Sabbah A; Lesellin J; Hassoun S; Sicard H; André C
Allerg Immunol (Paris); 1993 Jun; 25(6):241-7. PubMed ID: 8357473
[TBL] [Abstract][Full Text] [Related]
16. Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis.
Köberlein J; Mösges R
Immunotherapy; 2013 Jan; 5(1):13-21. PubMed ID: 23256794
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
18. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
19. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
20. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents.
Halken S; Agertoft L; Seidenberg J; Bauer CP; Payot F; Martin-Muñoz MF; Bartkowiak-Emeryk M; Vereda A; Jean-Alphonse S; Melac M; Le Gall M; Wahn U
Pediatr Allergy Immunol; 2010 Sep; 21(6):970-6. PubMed ID: 20718927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
